Plimasine en es it fr

Plimasine Brand names, Plimasine Analogs

Plimasine Brand Names Mixture

  • No information avaliable

Plimasine Chemical_Formula


Plimasine RX_link

Plimasine fda sheet

Plimasine FDA

Plimasine msds (material safety sheet)

Plimasine MSDS

Plimasine Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Plimasine Molecular Weight

233.306 g/mol

Plimasine Melting Point


Plimasine H2O Solubility


Plimasine State


Plimasine LogP


Plimasine Dosage Forms

Tablets; Tablets (sustained release)

Plimasine Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Plimasine Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Plimasine Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Plimasine side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Plimasine Patient Information

Plimasine Organisms Affected

Humans and other mammals